It was also demonstrated that kinase PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of TNBC, which is negative for the expression of ER, PR, and HER2, and is associated with a poorer prognosis among all types of BC [25]. The gene discussed is PIM1; the disease is breast cancer.